Company Dossier · Health Care
Abbott Laboratories
- S&P 500
- S&P 100
- Russell 1000
What Abbott Laboratories is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to March 31, 2026: $45.1 billion, up 6.6% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to March 31, 2026: $7.38 billion, up 11% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to March 31, 2026: $2.09 billion, down 8.7% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.89 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (October 21, 2026): sentiment 0.55 on a −1 to +1 scale (mixed), confidence 0.60 of 1.Palanor Discourse
- Guidance in the last 90 days: 0 outlook figures raised, 1 lowered, 1 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 20, 2026): 0 risk factors added, 1 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $46.9 million on the open market.SEC Form 4
- 2,988 institutional managers reported a position at June 30, 2026 (−130 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 125 (116 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Abbott Laboratories is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Expanding ↔ Retrenching
Withheld: 50% of the evidence is readable at this date (needs 60%).
- Capital spending—
- Debt raised—
- Buybacks vs capex—
- Hiring filings48th pct
- Deals and private raises49th pct
- Patent publications35th pct
Confident ↔ Hedging
Mixed
- Call sentiment34th pct
- Call confidence5th pct
- Guidance changes38th pct
- Risk factors added75th pct
- Insider open-market trades71st pct
- − Call confidence
- − Call sentiment
- + Risk factors added
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver57th pct
- Stress filings48th pct
Credit
How these are built →Abbott Laboratories's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$34.0B
- Due within a year $4.4B
- Longer term $29.6B
- Default point $19.2B (short + ½ long)
Finance leases included · Mar 31, 2026 filing
Bonds priced, last 12 months
$20.0B
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| Feb 23, 2026 | $1B | SOFR + 50bp | 2029 (3y) | — | — |
| Feb 23, 2026 | $2.25B | 3.700% | 2029 (3y) | +30bp | 3.745% |
| Feb 23, 2026 | $2.5B | 4.000% | 2031 (5y) | +45bp | 4.032% |
| Feb 23, 2026 | $2.75B | 4.300% | 2033 (7y) | +55bp | 4.331% |
| Feb 23, 2026 | $3.75B | 4.650% | 2036 (10y) | +65bp | 4.681% |
| Feb 23, 2026 | $2B | 4.750% | 2038 (12y) | +75bp | 4.781% |
| Feb 23, 2026 | $3.75B | 5.500% | 2056 (30y) | +80bp | 5.508% |
| Feb 23, 2026 | $2B | 5.600% | 2066 (40y) | +90bp | 5.608% |
From the pricing term sheets Abbott Laboratories filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Abbott Laboratories, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralAbbott Laboratories (ABT) Reports Q3 Results and Plans Nutrition Business Spin-Off
gurufocus.com · via Marketaux · Oct 21, 2026
- NeutralAbbott Laboratories (ABT) Dividend Stock Analysis
dividend-growth-stocks.com · via Marketaux · Oct 16, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 21, 2026LobbyingLobbying report (PHRONESISDC, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (DUDDINGTON GLOBAL STRATEGIES LLC)third_quarter 2026 · $0.0 million
- Oct 20, 2026LobbyingLobbying report (MARSHALL & POPP, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (THE DUBERSTEIN GROUP INC.)third_quarter 2026
- Oct 20, 2026LobbyingLobbying report (ABBOTT LABORATORIES)third_quarter 2026 · $1.3 million
- Oct 20, 2026LobbyingLobbying report (AKIN GUMP STRAUSS HAUER & FELD)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (LIBERTY PARTNERS GROUP, LLC)third_quarter 2026
- Oct 20, 2026LobbyingLobbying report (THE DUBERSTEIN GROUP INC.)third_quarter 2026
- Oct 20, 2026PatentPatent granted: ELECTROLYTIC CAPACITORUS 12770799
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Apr 27, 20268-KDirector or officer changeItem 5.02
- Apr 27, 20268-KShareholder vote resultsItem 5.07
- Mar 9, 20268-KMaterial agreement signedItem 1.01
- Feb 26, 20268-KMaterial agreement signedItem 1.01
- Feb 20, 202610-KAnnual report (10-K)0 risk factors added, 1 removed
- Dec 12, 20258-KDirector or officer changeItem 5.02
- Nov 20, 20258-KMaterial agreement signedItem 1.01
- Oct 14, 2025Risk event
- May 1, 20258-KDirector or officer changeItem 5.02
- Apr 28, 20258-KShareholder vote resultsItem 5.07
- Feb 26, 2025Risk event
- Feb 21, 202510-KAnnual report (10-K)0 risk factors added, 0 removed
- Nov 15, 20248-KDirector or officer changeItem 5.02
- Feb 16, 202410-KAnnual report (10-K)1 risk factors added, 0 removed
Peers
Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Molina Healthcare MOH | $44.5B | −$0.6B | Jun 30, 2026 |
| Thermo Fisher Scientific TMO | $46.3B | $7.3B | Jun 27, 2026 |
| Bristol Myers Squibb BMY | $49.2B | $11.4B | Jun 30, 2026 |
| Amgen AMGN | $38.1B | $10.2B | Jun 30, 2026 |
| Medtronic MDT | $37.5B | $6.1B | Jul 31, 2026 |
| Pfizer Inc. PFE | $63.7B | $11.0B | Jun 28, 2026 |
| AbbVie Inc. ABBV | $64.4B | $18.2B | Jun 30, 2026 |
| Merck & Co. MRK | $66.6B | $16.1B | Jun 30, 2026 |